Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002765 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin in Treating Patients With Leukemia or Lymphoma
A Phase 1 study of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00002765: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).
NCT00002765 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by National Cancer Institute (NCI). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002765, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of LMB-2 immunotoxin in treating patients who have leukemia or lymphoma.
Interventions
- BIOLOGICAL LMB-2 immunotoxin
Study Locations (2)
Maryland
- Laboratory of Molecular Biology - Bethesda
- Medicine Branch - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-04 |
| Phase | Phase 1 |
What the finished NCT00002765 record still lists
NCT00002765 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which LMB-2 immunotoxin is the first listed.
NCT00002765 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00002765 about?
NCT00002765 is a clinical study titled "Immunotoxin in Treating Patients With Leukemia or Lymphoma". RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of LMB-2 immunotoxin in treating patients who have leukemia or lymphoma.
What is the current status of trial NCT00002765?
This trial is currently completed. It is a Phase 1 study. The study started on 1996-04.
What conditions does trial NCT00002765 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00002765?
The interventions under investigation include: LMB-2 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002765?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002765 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia